CLIA Moderate Complexity Provision Should Provide Rapid HIV Test Access
This article was originally published in The Gray Sheet
Executive Summary
Expedited access to rapid HIV testing should be enabled under a special provision of the Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test category, FDA's Blood Products Advisory Committee concluded June 14.
You may also be interested in...
CLIA Waiver, Oral Fluid Claim Next For HHS-Backed OraQuick Rapid HIV Test
OraSure and FDA are discussing a CLIA waiver protocol the company has submitted for its OraQuick rapid HIV diagnostic test, which gained premarket approval Nov. 7
CLIA Waiver, Oral Fluid Claim Next For HHS-Backed OraQuick Rapid HIV Test
OraSure and FDA are discussing a CLIA waiver protocol the company has submitted for its OraQuick rapid HIV diagnostic test, which gained premarket approval Nov. 7
CDC Selects OraSure's OraQuick Rapid HIV-1/2 Test for MIRIAD Project
OraSure Technologies is hoping that the Centers for Disease Control and Prevention's inclusion of the OraQuick rapid HIV-1/2 test in a maternal AIDS intervention study will raise the product's visibility among U.S. public hospitals.